Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme

  1. Ruilope, L.M.
  2. Redón, J.
  3. Schmieder, R.
Zeitschrift:
Vascular Health and Risk Management

ISSN: 1176-6344

Datum der Publikation: 2007

Ausgabe: 3

Nummer: 1

Seiten: 1-9

Art: Rezension

GOOGLE SCHOLAR
Datenquelle: Scopus